Funding for this research was provided by:
DH | National Institute for Health Research (BRC-1215-2000)
Article History
Received: 17 November 2022
Accepted: 10 July 2023
First Online: 17 July 2023
Competing interests
: Daniel Freeman is a founder of Oxford VR, a University of Oxford spin-out company, which commercialises automated VR therapies. The other authors do not have any competing interests.